GGrantIndex
← Leaderboards

James Brugarolas

Dana-Farber Cancer Institute

$10,657,328
Attributed
$10,657,328
Total exposure
12
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $3.3M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$30,669,682 · 13

By mechanism

P50$26,179,498 · 9
R01$3,252,439 · 2
K08$820,758 · 1
R21$416,987 · 1

Top collaborators

Most similar at Dana-Farber Cancer Institute

Same institution · by research overlap

Others in their field

Top investigators on “Renal Carcinoma

Research focus

Renal CarcinomaInnovationTumorMedical CenterUniversitiesTexasProgramsGenesResearch PersonnelReportingEvaluationRenal Cell CarcinomaTranslationsTranslatingFundingMutationResearch StudyCollaborationsProteinsFoundationsMalignant NeoplasmsTranscription FactorSuccessMediating

Grant awards (53)

University of Texas Southwestern Medical Center SPORE in Kidney Cancer$2,336,997
P50 · FY2025 · CA · contact PI
Core A: Administrative Core$259,667
P50 · FY2025 · CA · contact PI
Project 1: Targeting HIF2 in Renal Cell Carcinoma$259,667
P50 · FY2025 · CA · contact PI
Developmental Research Program$259,666
P50 · FY2025 · CA · contact PI
University of Texas Southwestern Medical Center SPORE in Kidney Cancer$2,243,520
P50 · FY2024 · CA · contact PI
Project 1: Targeting HIF2 in Renal Cell Carcinoma$347,133
P50 · FY2024 · CA · contact PI
Developmental Research Program$214,340
P50 · FY2024 · CA · contact PI
Core A: Administrative Core$153,719
P50 · FY2024 · CA · contact PI
University of Texas Southwestern Medical Center SPORE in Kidney Cancer$2,173,408
P50 · FY2023 · CA · contact PI
Project 1: Targeting HIF2 in Renal Cell Carcinoma$339,342
P50 · FY2023 · CA · contact PI
Developmental Research Program$206,550
P50 · FY2023 · CA · contact PI
Core A: Administrative Core$145,930
P50 · FY2023 · CA · contact PI
University of Texas Southwestern Medical Center SPORE in Kidney Cancer$2,173,410
P50 · FY2022 · CA · contact PI
Project 1: Targeting HIF2 in Renal Cell Carcinoma$332,494
P50 · FY2022 · CA · contact PI
Dissecting the mechanism of cabozantinib anti-tumor effect in renal cancer$225,410
R21 · FY2022 · CA · contact PI
Developmental Research Program$208,995
P50 · FY2022 · CA · contact PI
Core A: Administrative Core$152,621
P50 · FY2022 · CA · contact PI
Dissecting the mechanism of cabozantinib anti-tumor effect in renal cancer$191,577
R21 · FY2021 · CA · contact PI
The University of Texas Southwestern Medical Center SPORE in Kidney Cancer$2,185,000
P50 · FY2020 · CA · contact PI
Project 1: Targeting HIF-2 for the Treatment of Clear-Cell Renal Cell Carcinoma$321,476
P50 · FY2020 · CA · contact PI
Developmental Research Program$180,905
P50 · FY2020 · CA · contact PI
Core A: Administrative Core$177,643
P50 · FY2020 · CA · contact PI
The University of Texas Southwestern Medical Center SPORE in Kidney Cancer$2,138,019
P50 · FY2019 · CA · contact PI
Project 1: Targeting HIF-2 for the Treatment of Clear-Cell Renal Cell Carcinoma$296,485
P50 · FY2019 · CA · contact PI
Developmental Research Program$166,562
P50 · FY2019 · CA · contact PI
Core A: Administrative Core$163,722
P50 · FY2019 · CA · contact PI
The University of Texas Southwestern Medical Center SPORE in Kidney Cancer$2,300,000
P50 · FY2018 · CA · contact PI
Evaluation of the BAP1 tumor suppressor gene in renal cell carcinoma$329,925
R01 · FY2018 · CA · contact PI
Project 1: Targeting HIF-2 for the Treatment of Clear-Cell Renal Cell Carcinoma$318,715
P50 · FY2018 · CA · contact PI
Developmental Research Program$179,349
P50 · FY2018 · CA · contact PI
Core A: Administrative Core$176,112
P50 · FY2018 · CA · contact PI
The University of Texas Southwestern Medical Center SPORE in Kidney Cancer$2,300,000
P50 · FY2017 · CA · contact PI
Evaluation of the BAP1 tumor suppressor gene in renal cell carcinoma$329,925
R01 · FY2017 · CA · contact PI
Project 1: Targeting HIF-2 for the Treatment of Clear-Cell Renal Cell Carcinoma$318,713
P50 · FY2017 · CA · contact PI
Developmental Research Program$179,349
P50 · FY2017 · CA · contact PI
Core A: Administrative Core$176,114
P50 · FY2017 · CA · contact PI
The University of Texas Southwestern Medical Center SPORE in Kidney Cancer$2,162,000
P50 · FY2016 · CA · contact PI
Evaluation of the BAP1 tumor suppressor gene in renal cell carcinoma$329,925
R01 · FY2016 · CA · contact PI
Project 1: Targeting HIF-2 for the Treatment of Clear-Cell Renal Cell Carcinoma$300,075
P50 · FY2016 · CA · contact PI
Developmental Research Program$168,543
P50 · FY2016 · CA · contact PI
Core A: Administrative Core$163,257
P50 · FY2016 · CA · contact PI
Evaluation of the BAP1 tumor suppressor gene in renal cell carcinoma$329,925
R01 · FY2015 · CA · contact PI
Evaluation of the BAP1 tumor suppressor gene in renal cell carcinoma$329,925
R01 · FY2014 · CA · contact PI
Regulation of the mTOR Pathway by Hypoxia and the REDD1 Protein$316,002
R01 · FY2012 · CA · contact PI
Regulation of the mTOR Pathway by Hypoxia and the REDD1 Protein$316,002
R01 · FY2011 · CA · contact PI
Regulation of the mTOR Pathway by Hypoxia and the REDD1 Protein$325,775
R01 · FY2010 · CA · contact PI
Regulation of the mTOR Pathway by Hypoxia and the REDD1 Protein$325,775
R01 · FY2009 · CA · contact PI
VEGF regulation by the TSC2 tumor suppressor$173,173
K08 · FY2009 · NS · contact PI
Regulation of the mTOR Pathway by Hypoxia and the REDD1 Protein$319,260
R01 · FY2008 · CA · contact PI
VEGF regulation by the TSC2 tumor suppressor$172,976
K08 · FY2008 · NS · contact PI
VEGF regulation by the TSC2 tumor suppressor$172,786
K08 · FY2007 · NS · contact PI
VEGF regulation by the TSC2 tumor suppressor$151,001
K08 · FY2006 · NS · contact PI
VEGF regulation by the TSC2 tumor suppressor$150,822
K08 · FY2005 · NS